Patentapplication WO2015024664 by CureVac discloses developmentof a mRNA-based personalized cancer vaccine encoding prostate cancer-associatedantigens, prostate-specific antigen), PSMA (prostate-specific membraneantigen), PSCA (prostate stem cell antigen), STEAP (six transmembraneepithelial antigen of the prostate), MUC1 (mucin 1) and PAP (prostaticacid phosphatase) for treating prostate cancer. Here, MUC1 is linked to prostate carcinoma.